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This study examines whether the glucose regulating enzymes mediate hypoglycaemic effect of diallyl disulphide 
(DADS) since the biochemical mechanisms by which the latter regulates hepatic glucose-metabolizing enzymes remain 
unknown. Hepatic hexokinase, glucose-6-P-D and pyruvate kinase are the important glucose metabolising enzymes that 
control blood glucose homeostasis and considered to be potential targets for antidiabetic drugs. DADS is an important 
phytoconstituent of garlic (Allium sativum Linn.) which has been reported to possess hypoglycaemic effect. Diabetes was 
induced in rats by alloxan and the diabetic rats were given DADS for 30 days and the effect was compared with the standard 
hypoglycaemic drug metformin. The levels of blood glucose and insulin were measured using spectrophotometer and by 
ELISA method respectively. Activities of hepatic hexokinase, glucose-6-PD, and pyruvate kinase enzymes in hepatic tissues 
were measured in DADS and metformin treated diabetic rats. DADS significantly reduced the level of blood glucose and 
simultaneously augmented those of insulin, pyruvate kinase, hexokinase and glucose-6-PD enzyme activities almost similar 
to metformin. The hypoglycaemic effect of this compound may be explained, in part, by its inhibition of these enzyme 
activities and improved hepatic glucose utilization. This observation offers scope for new therapeutic approach in treating 
diabetes particularly in insulin- resistant cases. 
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Diabetes mellitus (DM) is a metabolic syndrome 
characterised by hyperglycaemia with various 
pathological indicators often associated with 
abnormal lipid and glucose metabolism
1
. DM is 
caused by an insufficiency of either or both insulin 
secretion and action. Glucose is the required principle 
energy source for tissue cells and organs in humans
2
. 
However, chronic elevation of its levels results in 
diabetes and lead to secondary complications
3
. 
The liver plays a pivotal role in buffering the level 
of blood glucose by contributing either in hepatic 
glucose production (HGP) or utilization based on the 
prevailing plasma glucose level to maintain normal 
threshold value. The hepatocytes are coded with an 
array of regulatory mechanisms to maintain the process 
of glycogenolysis, glycolysis, glycogenesis, and 
gluconeogenesis
4
. There are several therapeutic options 
to maintain normoglycemia in diabetes individuals
5
. 
However, the most of the currently available 
antidiabetic medications such as biguanides, 
sulfonylureas, thiazolidinediones, and -glucosidase 
inhibitors used for the treatment of type 2 diabetes
6
 are 
also known to cause unwanted side effects and 
diminution after prolonged use
7
. Metformin is currently 
used as the drug of choice in the treatment of type 2 
diabetes mellitus
8
, being prescribed to at least 120 
million people worldwide. As established in large 
prospective controlled clinical trials, metformin 
improves glycaemic control and reduces cardiovascular 
complications in diabetic patients and is also used to 
prevent chronic hypoglycemia
9
. Hence, search for 
newer drugs becomes necessary and the medicinal 
plants serve as promising source of drug discovery.  
The traditionally used herbal products become the 
highly esteemed cradle of medicine
10
 and also 
contribute as drugs of modern medicine. In this 
aspect, there are more than 65 species of plants with 
hypoglycaemic properties
11
 as per the literature 
sources from numerous databases. One of the most 
dynamic plants is garlic (Allium sativum Linn.) that 
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displayed the significant hypoglycaemic effect in 
earlier studies
12,13
. In addition, it is also reported to 
possess anti-hyperglycemic, anti-atherogenic, anti-
hyperlipidemic properties and most of these activities 
were attributed to the principle compound DADS
14
. 
Ingestion of DADS decreases the risks of 
gastrointestinal cancers
15
 and also have the capability 
to modify numerous biological mechanisms that might 
influence the favourable action on colon carcinogenesis 
and has been shown to have antiproliferative action on 
breast and liver carcinogenesis
15
.  
Most of the oral hypoglycaemic drugs currently used 
for treating diabetes possess antioxidant properties in 
addition to hypoglycaemic activity
16
. However, the 
available antidiabetic drugs often provoke undesirable 
side effects on prolonged use, and hence drugs  
with antioxidant potential without side effects might 
signify a useful ancillary pharmacological approach to 
the successful management of diabetes and its 
complications
17
. DADS offer a therapeutic action in 




In this study, an effort has been made to assess the 
role of DADS on hepatic glucose utilization by 
regulating the glucose metabolising enzymes in diabetic 
rats and compare the action with metformin, a standard 
antidiabetic drug. 
 
Materials and Methods 
Chemicals 
The chemicals such as DADS, metformin, and 
alloxan were bought from Sigma Aldrich Chemicals  
(St. Louis, U.S.A.) and other organic solvents and 
reagents used were of analytical grade procured from 
Thermo Fisher Scientific, India. The serum insulin 
ELISA kits were purchased from Enzo Life Sciences, 
Inc., and standards for pyruvate kinase, glucose-6-PD, 
hexokinase obtained from Randox Laboratories. 
 
Animals 
Male Wistar rats (175±25 g) used for the studies were 
kept in clean polypropylene cages and maintained under 
standard laboratory conditions at (22±2°C and 12 h 
alternating light-dark cycle). They had free access to 
standard pellet diet (Hindustan Lever, Kolkata, India) 
and water ad libitum.  
 
Experimental design 
The rats were divided into four groups each 
comprising of six animals. Rats that received normal 
saline (1 mL/kg b.w., p.o.) served as normal control 
(Group 1). To 18 h fasted rats of other three  
groups, diabetes was induced by alloxan monohydrate 
(150 mg/kg; i.p.) dissolved in normal saline as a  
single dose. After 48 h of injection, hyperglycemia in rats 
was established by testing glucose positivity for  
3 successive days. Rats with blood-glucose levels above 
250 mg/dL were considered as diabetic and chosen  
for further studies
19
. Diabetic rats in group 2  
remained untreated while to group 3 and 4 animals, 
DADS (100 mg/kg/day, p.o.) and metformin  
(150 mg/kg/day, p.o.) were administered respectively for 
30 consecutive days.  
After the experimental period, the animals were 
sacrificed via sodium pentabarbitone injection and blood 
was collected in heparinized plain tubes instantly  
for assays. Liver tissue was removed and washed  
with saline and tissue homogenate was prepared using 
PBS and maintained at 4C until further assay. Blood 
plasma was separated by centrifugation (1700  g,  
15 min, 8°C) and immediately used for glucose 
measurement. 
 
Assay of Insulin 
Serum insulin level was measured by standard 
procedure using rat insulin ELISA kit
20
. During 
incubation, insulin in the sample reacts with peroxidase-
conjugated anti-insulin anti-bodies and they bound to the 
plate well. The bound conjugated insulin was identified 
by reacting with 3, 3, 5, 5-tetramethylbenzidine. The 
reaction was stopped by adding acid to give a 
colorimetric end-point and optical density was measured 
with a microplate auto reader at a wavelength of  
450 nm. The plasma glucose level was measured using 
the glucose diagnostic kit. 
 
Assay of Hexokinase 
The solution mixture contains 0.1 mL of 0.1 M 
ammonium phosphate buffer, pH 7.6, 0.1 mL of 
reduced diphosphopyridine nucleotide, 0.3 mL of 0.1% 
a-glycerophosphate dehydrogenase 0.1 mL of aldolase, 
0.1 mL 0.4% adenosine triphosphate, 0.1 mL 0.07 M 
MgCl2 and 0.1 mL of 0.1 M fructose-6-phosphate. To 
this mixture, 0.2mL of sample was added along with 
distilled water to get the final volume to 3 mL. 
Hexokinase activities were calculated as U/g tissue. 





Assay of pyruvate kinase 
Pyruvate kinase (PK) activity was determined in the 
liver homogenate of all the experimental groups. To  
0.1 mL of sample added 100 µL of 50 mM of glycyl 




glycine, 100 µL of 15 mM ethylene diamine tetra acetic 
acid (EDTA) and 100 µL of 5 mM potassium phosphate. 
The total activity of PK was resolute in the supernatants 




Assay of Glucose-6-Phosphate dehydrogenase 
The liver tissue (50 mg) homogenized in 200 μL 
assay buffer and centrifuged (13000  g, 10 min.). The 
final volume of test sample was adjusted to 50 μL/ 
well with assay buffer in a 96-well plate. About 92 μL 
assay buffer, 8 μL GDH developer, and 10 μL 2 M 
glucose were added to each well-comprising  
test samples. The mix was incubated for 3 min at  






Data obtained from the experiments are presented 
as the mean ± SD of six values. For statistical 
analysis, data were subjected to one-way analysis of 
variance (ANOVA) followed by Student’s t-test. A 
level of P <0.05, P <0.01, P <0.001 was taken as 
significant. The statistical analysis was done using the 
SPSS statistical package (Version 22.0). 
 
Results 
Effect of DADS on glucose and insulin levels 
The effect of DADS on the levels of blood glucose 
and plasma insulin in alloxan- induced diabetic rats  
are presented in (Table 1). Diabetic rats showed 
significantly (P <0.001) elevated fasting blood glucose 
levels and decreased insulin levels when compared  
to control rats. The altered levels of insulin and  
blood glucose were reverted to near normal values  
after oral treatment with DADS suggesting the 
regulation of glucose homeostasis. The normalising 
level of insulin in the DADS fed group reveals  
the hypoglycaemic action which is comparable with that 
of metformin activity. 
 
Effect of DADS on glucose metabolising enzymes  
The results indicated the role of DADS in influencing 
hepatic glucose utilization in alloxan diabetic liver by 
increasing the activities of glucose metabolising enzyme 
hexokinase and regulatory enzymes pyruvate kinase, and 
G-6PD are presented in (Figs. 1-3). It is evident from the 
data that activities of pyruvate kinase, hexokinase and 
glucose-6-PD were significantly (P <0.01) lowered in 
the diabetic group when compared to normal rats 
whereas, the enzyme activities are significantly elevated 
in DADS and metformin- treated rats as compared to 
diabetic rats. DADS influence increased glucose 
utilization by increasing glycolytic enzyme activity 
which is comparable with standard anti-diabetic drug 
metformin. 
Table 1— Effect of DADS and metformin on plasma glucose  
and insulin levels in diabetic rats. 
Groups Glucose (mg/dL) Insulin (pg/mL) 
Normal control 85.76 ±1.33 0.36 ± 0.00 
Diabetic rats 286.70 ± 1.20*** 0.15 ± 0.00*** 
Diabetic + DADS 99.46 ± 0.32c 0.27 ± 0.00 c 
Diabetic + Metformin 108.80 ± 0.74 @@@ 0.23 ± 0.00@@@ 
Results are expressed as Mean ± SD (n =6); ***P <0.001 as 
compared to normal control group; @@@,cP <0.001 as compared to 
DM control group. 
 
 
Fig. 1 — Effect of DADS and metformin on hepatic Hexokinase 
activities in diabetes mellitus induced rats. Results are expressed 
as Mean ± SD (n =6); ***P <0.001 as compared to normal  
control group; cP <0.001 as compared to DM control group; 




Fig. 2 — Effect of DADS and metformin on hepatic Pyruvate 
kinase activities in diabetes mellitus induced rats. Results are 
expressed as Mean ± SD (n =6); ***P <0.001 as compared to 
normal control group; bP <0.01 as compared to DM control group; 
@@P <0.01 as compared to DM control group 





The major goal of diabetes management is to keep the 
level of blood glucose in the normal range by proper 
utilisation of cells. Blood glucose control is an important 
constituent in preventing acute or long-term diabetic 
complications
24
. Though insulin resistance is the starting 
pathogenic factor in type 2 diabetes, β-cell failure is 
responsible for insulin deficiency and impaired glucose 
tolerance to explicit type 2 diabetes
25
. Insulin resistance 
in the peripheral tissues allied with increased hepatic 
glucose production to release into blood stream are 
responsible for increased fasting blood glucose levels in 
diabetic rats.  
DADS treatment for 30 days reduced the level of 
blood glucose in alloxan-induced diabetic rats, a 
desirable criterion for any potential anti-diabetic agent 
and also no hypoglycaemic condition was observed in 
treated group
26
. DADS treatment also significantly 
increased the low serum insulin and induced attenuation 
of glucose metabolic disorder through regulations of 
glucose metabolic enzymes.  
Diabetes induced hyperglycaemia is due to lack of 
insulin or subnormal functioning of insulin arises 
because of disturbances in glucose metabolism caused 
by a reduced activity of several regulatory key enzymes 
of glycolysis such as HK, PK and G-6PD, resulting in 
impairment in glucose utilization by peripheral cells and 
augmented hepatic glucose production. In diabetic 
condition, the activities of these enzymes are hindered 
due to insulin resistance because it is an insulin-
dependent enzyme
27
. Markedly reduced level of insulin 
diabetic rats eventually leads to the impairment in the 
effect of hexokinase since insulin deficiency which 
finally leads to the onset of chronic hyperglycemia 
which is a hallmark of diabetes
28
.  
The activities of key enzymes of carbohydrate 
metabolism such as hexokinase, pyruvate kinase, and 
glucose-6-phosphate dehydrogenase in hepatic tissues 
were evaluated to establish the regulatory effect of 
DADS in glucose homeostasis in comparison with the 
hypoglycaemic drug Metformin. An increase in 
glycolytic enzymes (HK and PK) enhances peripheral 
glucose utilization through glycolysis and could 
contribute to the anti-hyperglycaemic effect of DADS. 
The hypoglycaemic action of DADS is highly operative 
in bringing down the level of blood glucose to near 
normoglycemia and also increased glucose utilization 
through glycolysis by increasing the activities of key 
enzymes. This may be due to its ability to inhibit 




Goudappala et al and Yusuf et al have reported that 
hypoglycemic effects of the antidiabetic drug are due to 
the mechanism arbitrated by hepatic glucose-regulating 
enzymes
29,30
. Upon oral treatment with DADS, the 
diabetic rats displayed not only the elevated hepatic 
hexokinase, pyruvate kinase, and G-6-PDactivity but 
also significantly lowered the insulin levels compared 
with the standard metformin group, which might explain 
the glucose-lowering activity of DADS. 
 
Conclusion 
The results of the study revealed how the regulation 
of glucose metabolising enzymes could be utilised as 
targets in treating type 2 diabetes either by directly using 
targeted inhibition or indirectly as a consequence of 
inducing energy stress. The later mechanism may 
contribute significantly to the apparent glucose- 
lowering effect of many biologically active secondary 
metabolites. The increased activity of these glucose 
regulating enzymes by DADS facilitates glucose 
oxidation leading to controlled glucose homeostasis in 
diabetic conditions. However, further studies are 
warranted at molecular levels to elucidate the actual 
mechanism of action of DADS by which hypoglycaemic 
effect is brought about. 
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Fig. 3 — Effect of DADS and metformin on hepatic Glucose-6-
phosphate dehydrogenase activities in diabetes mellitus induced 
rats. Results are expressed as Mean ± SD (n =6); **P <0.01 as 
compared to normal control group; aP <0.05 as compared to DM 
control group; @P <0.05 as compared to DM control group 
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